William Tabayoyong1, Ashish M Kamat2. 1. The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 1373, Houston, TX, 77030, USA. 2. The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 1373, Houston, TX, 77030, USA. akamat@mdanderson.org.
Abstract
PURPOSE OF REVIEW: We summarize the current literature regarding the available urinary biomarkers for the detection and surveillance of bladder cancer. RECENT FINDINGS: Four urinary biomarkers have FDA approval for the detection of bladder cancer; however, they have not supplanted cystoscopy and urine cytology as the gold standard. Recent technological advances in next-generation sequencing have allowed the field of urinary biomarker research to move beyond protein biomarkers and now include genomic, transcriptomic, and epigenetic panels. The search for a noninvasive, inexpensive urinary biomarker for the detection of bladder cancer that can replace cystoscopy and cytology continues. There are several promising genomic, transcriptomic, and epigenetic marker panels in development; however, these new tests require further prospective validation before widespread clinical implementation.
PURPOSE OF REVIEW: We summarize the current literature regarding the available urinary biomarkers for the detection and surveillance of bladder cancer. RECENT FINDINGS: Four urinary biomarkers have FDA approval for the detection of bladder cancer; however, they have not supplanted cystoscopy and urine cytology as the gold standard. Recent technological advances in next-generation sequencing have allowed the field of urinary biomarker research to move beyond protein biomarkers and now include genomic, transcriptomic, and epigenetic panels. The search for a noninvasive, inexpensive urinary biomarker for the detection of bladder cancer that can replace cystoscopy and cytology continues. There are several promising genomic, transcriptomic, and epigenetic marker panels in development; however, these new tests require further prospective validation before widespread clinical implementation.
Entities:
Keywords:
Bladder cancer; Urinary biomarker; Urothelial cancer
Authors: Vinata B Lokeshwar; Tomonori Habuchi; H Barton Grossman; William M Murphy; Stefan H Hautmann; George P Hemstreet; Aldo V Bono; Robert H Getzenberg; Peter Goebell; Bernd J Schmitz-Dräger; Jack A Schalken; Yves Fradet; Michael Marberger; Edward Messing; Michael J Droller Journal: Urology Date: 2005-12 Impact factor: 2.649
Authors: M F Sarosdy; M A Hudson; W J Ellis; M S Soloway; R deVere White; J Sheinfeld; M V Jarowenko; P F Schellhammer; E W Schervish; J V Patel; G W Chodak; D L Lamm; R D Johnson; M Henderson; G Adams; B A Blumenstein; K R Thoelke; R D Pfalzgraf; H A Murchison; S L Brunelle Journal: Urology Date: 1997-09 Impact factor: 2.649
Authors: C Billerey; D Chopin; M H Aubriot-Lorton; D Ricol; S Gil Diez de Medina; B Van Rhijn; M P Bralet; M A Lefrere-Belda; J B Lahaye; C C Abbou; J Bonaventure; E S Zafrani; T van der Kwast; J P Thiery; F Radvanyi Journal: Am J Pathol Date: 2001-06 Impact factor: 4.307
Authors: Pierre I Karakiewicz; Serge Benayoun; Craig Zippe; Gerson Lüdecke; Hans Boman; Marta Sanchez-Carbayo; Roberto Casella; Christine Mian; Martin G Friedrich; Sanaa Eissa; Hideyuki Akaza; Hartwig Huland; Hans Hedelin; Raina Rupesh; Naoto Miyanaga; Arthur I Sagalowsky; Michael J Marberger; Shahrokh F Shariat Journal: BJU Int Date: 2006-03-17 Impact factor: 5.588
Authors: Rui Batista; Nuno Vinagre; Sara Meireles; João Vinagre; Hugo Prazeres; Ricardo Leão; Valdemar Máximo; Paula Soares Journal: Diagnostics (Basel) Date: 2020-01-13